Abstract:
Pulmonary hypertension (PH) is a progressive and complex pulmonary vascular disease with poor prognosis. The aim of this study was to provide a new understanding of the lung pathology of disease and a noninvasive method in monitoring the establishment of animal models for basic and clinical studies of PH, indeed to explore clinical application value of lung ultrasound for patients with PH. Totally 32 male SD rats were randomly divided into control group, MCT (monocrotaline) group, PDTC (pyrrolidine dithiocarbamate) group, and NS (normal saline) group. Rats in the MCT group, PDTC group, and NS group received single intraperitoneal injection of MCT, while the control group received the same dose of NS. Then, PDTC group and NS group received PDTC and NS daily for treatment at the end of the model. Each group received lung ultrasound examination and measurement of pulmonary arterial pressure (PAP). Then, the rats were sacrificed to take the lung specimens to being observed. The ultrasound and pathological results were analyzed with a semiquantitative score. With the pulmonary artery pressure increases, the MCT group had a higher pulmonary ultrasound score and pathological score compared with the control group (p < 0.05). After PDTC treatment, the pulmonary ultrasound score and the pathological score decline (p < 0.05). We investigated both lung ultrasound scores, and the pathological scores were positively correlated with mean pulmonary artery pressure (mPAP) (both r > 0.8, p < 0.0001). Moreover, lung ultrasound scores were positively correlated with pathological scores (r > 0.8, p < 0.0001). We elucidated lung ultrasound evaluation providing more evidence for the management of PH in the rat model. Moreover, lung ultrasound provided a noninvasive method in monitoring the establishment of animal models for basic and clinical studies of PH.
摘要:
肺动脉高压(PH)是一种进展性复杂的肺血管疾病,预后不良。这项研究的目的是提供对疾病的肺部病理学的新认识,并为建立PH的基础和临床研究的动物模型提供一种非侵入性的监测方法。探讨肺部超声对PH患者的临床应用价值。将32只雄性SD大鼠随机分为对照组,MCT(野百合碱)组,PDTC(吡咯烷二硫代氨基甲酸酯)基团,和NS(生理盐水)组。MCT组大鼠,PDTC组,NS组一次性腹腔注射MCT,对照组给予相同剂量的NS。然后,PDTC组和NS组在模型结束时每天接受PDTC和NS治疗。每组均接受肺部超声检查并测量肺动脉压(PAP)。然后,处死大鼠取肺标本进行观察。超声和病理结果以半定量评分进行分析。随着肺动脉压力的增加,MCT组肺超声评分和病理评分均高于对照组(p<0.05)。PDTC治疗后,肺超声评分与病理评分下降(p<0.05)。我们调查了两个肺部超声评分,病理评分与平均肺动脉压(mPAP)呈正相关(均r>0.8,p<0.0001)。此外,肺超声评分与病理评分呈正相关(r>0.8,p<0.0001)。我们阐明了肺超声评估,为大鼠模型中PH的管理提供了更多证据。此外,肺部超声为建立PH的基础和临床研究动物模型提供了一种无创监测方法。